Sivik Global Healthcare LLC Reduces Position in Agilent Technologies, Inc. $A

Key Points

• Sivik Global Healthcare LLC has reduced its stake in Agilent Technologies by 10.0%, now holding 45,000 shares which represent 1.4% of its investment portfolio.
• Several hedge funds, including Generation Investment Management and UBS AM, have increased their positions in Agilent Technologies, reflecting a positive market sentiment.
• Analysts have raised their price targets for Agilent Technologies, with UBS Group setting a target of $170.00 and an overall average target of $148.69.

Sivik Global Healthcare LLC decreased its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 10.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,000 shares of the medical research company's stock after selling 5,000 shares during the period. Agilent Technologies accounts for 1.4% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 20th biggest position. Sivik Global Healthcare LLC's holdings in Agilent Technologies were worth $5,310,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of A. Generation Investment Management LLP grew its position in shares of Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company's stock valued at $582,976,000 after purchasing an additional 824,243 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Agilent Technologies by 18.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company's stock valued at $448,748,000 after purchasing an additional 604,124 shares during the period. Mackenzie Financial Corp grew its position in shares of Agilent Technologies by 141.5% in the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company's stock valued at $109,481,000 after purchasing an additional 548,344 shares during the period. Woodline Partners LP grew its position in shares of Agilent Technologies by 681.6% in the first quarter. Woodline Partners LP now owns 522,073 shares of the medical research company's stock valued at $61,072,000 after purchasing an additional 455,276 shares during the period. Finally, Parnassus Investments LLC grew its position in shares of Agilent Technologies by 38.3% in the first quarter. Parnassus Investments LLC now owns 1,577,999 shares of the medical research company's stock valued at $184,594,000 after purchasing an additional 437,242 shares during the period.

Analysts Set New Price Targets

A number of brokerages have recently commented on A. Wells Fargo & Company lifted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Monday, September 15th. Robert W. Baird lifted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Rothschild Redb raised Agilent Technologies to a "strong-buy" rating in a research report on Wednesday. UBS Group raised Agilent Technologies from a "neutral" rating to a "buy" rating and boosted their price target for the company from $130.00 to $170.00 in a research report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on Agilent Technologies from $155.00 to $165.00 and gave the company an "overweight" rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $148.69.

Agilent Technologies Trading Down 2.5%

Shares of A opened at $136.62 on Friday. The stock's 50-day moving average is $125.04 and its two-hundred day moving average is $117.03. The stock has a market cap of $38.73 billion, a PE ratio of 32.07, a P/E/G ratio of 4.46 and a beta of 1.26. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts' consensus estimates of $1.37. The company had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm's quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Tuesday, September 30th. Agilent Technologies's payout ratio is currently 23.24%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.